{"id":"NCT02452931","sponsor":"Tolmar Inc.","briefTitle":"Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty","officialTitle":"An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-31","primaryCompletion":"2018-09-05","completion":"2018-09-05","firstPosted":"2015-05-25","resultsPosted":"2020-05-20","lastUpdate":"2020-06-02"},"enrollment":64,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Precocious Puberty, Central"],"interventions":[{"type":"DRUG","name":"Leuprolide Acetate 45 mg","otherNames":[]}],"arms":[{"label":"Assigned Intervention","type":"EXPERIMENTAL"}],"summary":"This study determines the effectiveness of leuprolide acetate 45 mg for injectable suspension for treatment of children with Central Precocious Puberty.","primaryOutcome":{"measure":"Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 6 Months.","timeFrame":"6 months","effectByArm":[{"arm":"Assigned Intervention","deltaMin":54,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":20,"countries":["United States","Argentina","Canada","Chile","Mexico","New Zealand"]},"refs":{"pmids":["32738042"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":64},"commonTop":["Nasopharyngitis","Pyrexia","Headache","Cough","Abdominal pain"]}}